The in vitro effect of SB-497115 (Eltrombopag) on megakaryopoiesis of patients with low/intermediate-1 IPSS myelodysplastic syndrome

被引：0
|
作者：
Papadaki, H. [1 ]
Mavroudi, I. [1 ]
Psyllaki, M. [1 ]
Pyrovolaki, K. [1 ]
Papadaki, V. [1 ]
Kalpadakis, C. [1 ]
Mastrodimou, S. [1 ]
Kaparou, M. [1 ]
Kanellou, P. [1 ]
Gvazava, G. [1 ]
机构：
[1] Univ Crete, Sch Med, Dept Haematol, Iraklion, Greece
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70065-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S47 / S48
页数：2
相关论文
共 50 条
  • [21] Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS)
    Vicente, Alana
    Gutierrez-Rodrigues, Fernanda
    Giudice, Valentina
    Wu, Zhijie
    Kajigaya, Sachiko
    Ibanez, Maria del Pilar Fernandez
    Albitar, Maher
    Weinstein, Barbara
    Calvo, Katherine R.
    Townsley, Danielle M.
    Scheinberg, Phillip
    Dunbar, Cynthia E.
    Young, Neal S.
    Winkler, Thomas
    [J]. BLOOD, 2018, 132
  • [22] 5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program
    Musto, Luca Maurillo
    Spagnoli, Alessandra
    Gozzini, Antonella
    Rivellini, Flavia
    Tatarelli, Caterina
    Lunghi, Monia
    Fili, Carla
    Orciuolo, Enrico
    Ciuffreda, Lucia
    Vigna, Ernesto
    Della Cioppa, Paola
    Candoni, Anna
    Ferrero, Dario
    Palmieri, Salvatore
    Palumbo, Giuseppe
    Di Renzo, Nicola
    Oliva, Esther
    Sanpaolo, Grazia
    Pastore, Domenico
    Tonso, Anna
    Santagostino, Alberto
    Rocco, Stefano
    Villani, Oreste
    D'Auria, Fiorella
    D'Arco, Alfonso Maria
    Gaidano, Gianluca
    Galimberti, Sara
    Russo, Domenico
    Venditti, Adriano
    Aloe-Spiriti, Maria Antonietta
    Leone, Giuseppe
    Santini, Valeria
    [J]. BLOOD, 2008, 112 (11) : 926 - 927
  • [23] Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
    Komrokji, Rami S.
    Al Ali, Najla H.
    Padron, Eric
    Cogle, Christopher
    Tinsley, Sara
    Sallman, David
    Lancet, Jeffrey E.
    Lis, Alan F.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 251 - 254
  • [24] ARCADE (20090160): A randomized controlled trial of darbepoetin alpha in anemic patients with low or intermediate-1 risk myelodysplastic syndrome (MDS)
    Gasal, E.
    Pan, C.
    Tankersley, C.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S166 - S167
  • [25] Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)
    Oliva, Esther Natalie
    Santini, Valeria
    Zini, Gina
    Palumbo, Giuseppe A.
    Poloni, Antonella
    Cortelezzi, Agostino
    Voso, Maria Teresa
    Molteni, Alfredo
    Sanpaolo, Grazia
    Marino, Antonio
    Roda, Filippo
    Alati, Caterina
    Ronco, Francesca
    Di Raimondo, Francesco
    Leoni, Pietro
    Alimena, Giuliana
    Finotto, Silvia
    Latagliata, Roberto
    Nobile, Francesco
    [J]. BLOOD, 2012, 120 (21)
  • [26] Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.
    Jabbour, Elias J.
    Daver, Naval G.
    Dong, Tina
    Kadia, Tapan M.
    O'Brien, Susan
    Cortes, Jorge E.
    Ravandi, Farhad
    Pemmaraju, Naveen
    Ghanem, Hady
    Faderl, Stefan
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2012, 120 (21)
  • [27] Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome
    Chien, Kelly S.
    Kim, Kunhwa
    Nogueras-Gonzalez, Graciela M.
    Borthakur, Gautam
    Naqvi, Kiran
    Daver, Naval G.
    Montalban-Bravo, Guillermo
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Alvarado, Yesid
    Andreeff, Michael
    Bose, Prithviraj
    Jain, Nitin
    Kadia, Tapan M.
    Huang, Xuelin
    Sheppard, Kimberly B.
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (03) : 378 - 387
  • [28] Eltrombopag As Initial Monotherapy for Transfusion Dependent Patients with Low to Intermediate Risk-1 Myelodysplastic Syndrome: Single Center Experience
    Shen, Yingying
    Li, Hangchao
    Xiang, Jingjing
    Zhu, Ni
    Li, Yuzhu
    Liu, Qi
    Dong, Huijie
    Wang, Bo
    Ye, Baodong
    Lin, Shengyun
    Shen, Yiping
    Wu, Dijiong
    [J]. BLOOD, 2021, 138
  • [29] Phase II Study of the Histone Deacetylase Inhibitor Panabinostat (LBH589) in Patients with Low or Intermediate-1 Risk Myelodysplastic syndrome
    Dimicoli, Sophie
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Estrov, Zeev
    Yang, Hui
    Kelly, Mary A.
    Pierce, Sherry
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2011, 118 (21) : 755 - 755
  • [30] Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome
    Dimicoli, Sophie
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Estrov, Zeev
    Yang, Hui
    Kelly, Mary
    Pierce, Sherry
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (01) : 127 - 129
12345